Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,22902104,limits of detections (LOD),"The proposed method achieved limits of detections (LOD) varied from 1.2 × 10(-7) to 9.5 × 10(-7)g/L based on a signal-to-noise of 3 (S/N=3) with 751- to 1372-fold increases in detection sensitivity for analytes, and it was successfully applied to the pharmacokinetic study of three antihistamines in human urine after an oral administration.",Trace analysis of three antihistamines in human urine by on-line single drop liquid-liquid-liquid microextraction coupled to sweeping micellar electrokinetic chromatography and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22902104/),[g] / [l],1.2 × 10(-7),3996,DB01114,Chlorphenamine
,22902104,limits of detections (LOD),"The proposed method achieved limits of detections (LOD) varied from 1.2 × 10(-7) to 9.5 × 10(-7)g/L based on a signal-to-noise of 3 (S/N=3) with 751- to 1372-fold increases in detection sensitivity for analytes, and it was successfully applied to the pharmacokinetic study of three antihistamines in human urine after an oral administration.",Trace analysis of three antihistamines in human urine by on-line single drop liquid-liquid-liquid microextraction coupled to sweeping micellar electrokinetic chromatography and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22902104/),[g] / [l],9.5 × 10(-7),3997,DB01114,Chlorphenamine
,22902104,signal-to-noise,"The proposed method achieved limits of detections (LOD) varied from 1.2 × 10(-7) to 9.5 × 10(-7)g/L based on a signal-to-noise of 3 (S/N=3) with 751- to 1372-fold increases in detection sensitivity for analytes, and it was successfully applied to the pharmacokinetic study of three antihistamines in human urine after an oral administration.",Trace analysis of three antihistamines in human urine by on-line single drop liquid-liquid-liquid microextraction coupled to sweeping micellar electrokinetic chromatography and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22902104/),,3,3998,DB01114,Chlorphenamine
,22902104,S/N,"The proposed method achieved limits of detections (LOD) varied from 1.2 × 10(-7) to 9.5 × 10(-7)g/L based on a signal-to-noise of 3 (S/N=3) with 751- to 1372-fold increases in detection sensitivity for analytes, and it was successfully applied to the pharmacokinetic study of three antihistamines in human urine after an oral administration.",Trace analysis of three antihistamines in human urine by on-line single drop liquid-liquid-liquid microextraction coupled to sweeping micellar electrokinetic chromatography and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22902104/),,3,3999,DB01114,Chlorphenamine
,2107240,serum-elimination half-life,The mean serum-elimination half-life of terfenadine metabolite I was 8.7 +/- 3.7 hours.,Pharmacokinetics and pharmacodynamics of terfenadine and chlorpheniramine in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2107240/),h,8.7,13311,DB01114,Chlorphenamine
,2107240,maximum wheal suppression,"After terfenadine ingestion, significant wheal suppression occurred from 2 to 24 hours compared to predose wheal size, with maximum wheal suppression, 42 +/- 13% to 60 +/- 16% from 2 to 12 hours.",Pharmacokinetics and pharmacodynamics of terfenadine and chlorpheniramine in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2107240/),%,42,13312,DB01114,Chlorphenamine
,2107240,maximum wheal suppression,"After terfenadine ingestion, significant wheal suppression occurred from 2 to 24 hours compared to predose wheal size, with maximum wheal suppression, 42 +/- 13% to 60 +/- 16% from 2 to 12 hours.",Pharmacokinetics and pharmacodynamics of terfenadine and chlorpheniramine in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2107240/),%,60,13313,DB01114,Chlorphenamine
,2107240,serum-elimination half-life,The mean serum-elimination half-life of chlorpheniramine was 22.6 +/- 11.0 hours.,Pharmacokinetics and pharmacodynamics of terfenadine and chlorpheniramine in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2107240/),h,22.6,13314,DB01114,Chlorphenamine
,2107240,maximum wheal suppression,"After chlorpheniramine ingestion, significant wheal suppression occurred from 1 to 10 hours, inclusive, compared to predose wheal size, with maximum wheal suppression, 36 +/- 11% to 37 +/- 11% from 5 to 6 hours.",Pharmacokinetics and pharmacodynamics of terfenadine and chlorpheniramine in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2107240/),%,36,13315,DB01114,Chlorphenamine
,2107240,maximum wheal suppression,"After chlorpheniramine ingestion, significant wheal suppression occurred from 1 to 10 hours, inclusive, compared to predose wheal size, with maximum wheal suppression, 36 +/- 11% to 37 +/- 11% from 5 to 6 hours.",Pharmacokinetics and pharmacodynamics of terfenadine and chlorpheniramine in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2107240/),%,37,13316,DB01114,Chlorphenamine
,2107240,maximum flare suppression,"Significant flare suppression occurred from 1 to 12 hours, with maximum flare suppression of 43 +/- 14% to 46 +/- 19% at 2, 5, and 6 hours (p less than 0.01).",Pharmacokinetics and pharmacodynamics of terfenadine and chlorpheniramine in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2107240/),%,43,13317,DB01114,Chlorphenamine
,2107240,maximum flare suppression,"Significant flare suppression occurred from 1 to 12 hours, with maximum flare suppression of 43 +/- 14% to 46 +/- 19% at 2, 5, and 6 hours (p less than 0.01).",Pharmacokinetics and pharmacodynamics of terfenadine and chlorpheniramine in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2107240/),%,46,13318,DB01114,Chlorphenamine
,15303659,recovery,"The within-day and between-day RSD were less than 12.4%, and the average recovery was between 97.3% - 109.4%.",[Simultaneous determination of pseudoephedrine and chlorpheniramine in human plasma by HPLC-UV detection method]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15303659/),%,97.3,14290,DB01114,Chlorphenamine
,15303659,recovery,"The within-day and between-day RSD were less than 12.4%, and the average recovery was between 97.3% - 109.4%.",[Simultaneous determination of pseudoephedrine and chlorpheniramine in human plasma by HPLC-UV detection method]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15303659/),%,109.4,14291,DB01114,Chlorphenamine
,15491104,flow-rate,"The mobile phase consisted of methanol-water-formic acid (70:30:1), at a flow-rate of 0.5 mL x min(-1).",[Determination of dextrorphan in human plasma and pharmacokinetic study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15491104/),[ml] / [min],0.5,27108,DB01114,Chlorphenamine
,15491104,Tmax,"Pharmacokinetic parameters of dextrorphan was obtained as follows: Tmax was (2.1 +/- 0.7) h, Cmax was (14 +/- 8) microg x L(-1), T1/2 was (3.8 +/- 1.8) h, AUC0-t was (60 +/- 37) microg x h x L(-1).",[Determination of dextrorphan in human plasma and pharmacokinetic study]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15491104/),h,2.1,27109,DB01114,Chlorphenamine
,15491104,Cmax,"Pharmacokinetic parameters of dextrorphan was obtained as follows: Tmax was (2.1 +/- 0.7) h, Cmax was (14 +/- 8) microg x L(-1), T1/2 was (3.8 +/- 1.8) h, AUC0-t was (60 +/- 37) microg x h x L(-1).",[Determination of dextrorphan in human plasma and pharmacokinetic study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15491104/),[μg] / [l],14,27110,DB01114,Chlorphenamine
,15491104,T1/2,"Pharmacokinetic parameters of dextrorphan was obtained as follows: Tmax was (2.1 +/- 0.7) h, Cmax was (14 +/- 8) microg x L(-1), T1/2 was (3.8 +/- 1.8) h, AUC0-t was (60 +/- 37) microg x h x L(-1).",[Determination of dextrorphan in human plasma and pharmacokinetic study]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15491104/),h,3.8,27111,DB01114,Chlorphenamine
,15491104,AUC0-t,"Pharmacokinetic parameters of dextrorphan was obtained as follows: Tmax was (2.1 +/- 0.7) h, Cmax was (14 +/- 8) microg x L(-1), T1/2 was (3.8 +/- 1.8) h, AUC0-t was (60 +/- 37) microg x h x L(-1).",[Determination of dextrorphan in human plasma and pharmacokinetic study]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15491104/),[h·μg] / [l],60,27112,DB01114,Chlorphenamine
,9158881,AUC ratios,"The AUC ratios between CSF and plasma for hydroxyzine after intranasal and intra-arterial administration were 4.0 and 0.4, respectively.",Distribution of antihistamines into the CSF following intranasal delivery. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9158881/),,4.0,27318,DB01114,Chlorphenamine
,9158881,AUC ratios,"The AUC ratios between CSF and plasma for hydroxyzine after intranasal and intra-arterial administration were 4.0 and 0.4, respectively.",Distribution of antihistamines into the CSF following intranasal delivery. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9158881/),,0.4,27319,DB01114,Chlorphenamine
,9158881,AUC ratios,"The AUC ratios for triprolidine, the other antihistamine with measurable CSF concentrations, were 0.5 and 0.7, respectively.",Distribution of antihistamines into the CSF following intranasal delivery. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9158881/),,0.5,27320,DB01114,Chlorphenamine
,9158881,AUC ratios,"The AUC ratios for triprolidine, the other antihistamine with measurable CSF concentrations, were 0.5 and 0.7, respectively.",Distribution of antihistamines into the CSF following intranasal delivery. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9158881/),,0.7,27321,DB01114,Chlorphenamine
,7120098,plasma elimination half-life,The average plasma elimination half-life of chlorpheniramine was calculated to be approximately 18.3 hr.,Bioavailability of regular and controlled-release chlorpheniramine products. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7120098/),h,18.3,28404,DB01114,Chlorphenamine
,7299679,volume of distribution at steady state,The volume of distribution at steady state ranged from 1.20 to 5.46 liters/kg.,Pharmacokinetics of intravenous chlorpheniramine in children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7299679/),[l] / [kg],1.20 to 5.46,33208,DB01114,Chlorphenamine
,7299679,serum clearance,The chlorpheniramine serum clearance varied approximately twofold (234-470 ml/hr/kg) and generally decreased with age.,Pharmacokinetics of intravenous chlorpheniramine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7299679/),[ml] / [h·kg],234-470,33209,DB01114,Chlorphenamine
,7299679,elimination half-life,"The chlorpheniramine elimination half-life in children (mean of 9.6 hr) appeared shorter than that in adults, probably due to higher chlorpheniramine serum clearance in children.",Pharmacokinetics of intravenous chlorpheniramine in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7299679/),h,9.6,33210,DB01114,Chlorphenamine
,10897096,Cmax,"For the reference formulation, Cmax and AUC values were higher for (+)S-chlorpheniramine ((+)S-CPAM) compared to (-)R-chlorpheniramine ((-)R-CPAM) (13.3 vs.",Stereospecific versus nonstereospecific assessments for the bioequivalence of two formulations of racemic chlorpheniramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10897096/),,13,34973,DB01114,Chlorphenamine
,10897096,Clt/F,"222 ng/ml/h, respectively) while Clt/F and Vd/F were lower (9.8 vs. 17.6 l/h and 321 vs. 627 l, respectively).",Stereospecific versus nonstereospecific assessments for the bioequivalence of two formulations of racemic chlorpheniramine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10897096/),[l] / [h],9.8,34974,DB01114,Chlorphenamine
,10897096,Vd/F,"222 ng/ml/h, respectively) while Clt/F and Vd/F were lower (9.8 vs. 17.6 l/h and 321 vs. 627 l, respectively).",Stereospecific versus nonstereospecific assessments for the bioequivalence of two formulations of racemic chlorpheniramine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10897096/),l,321,34975,DB01114,Chlorphenamine
,10897096,Vd/F,"222 ng/ml/h, respectively) while Clt/F and Vd/F were lower (9.8 vs. 17.6 l/h and 321 vs. 627 l, respectively).",Stereospecific versus nonstereospecific assessments for the bioequivalence of two formulations of racemic chlorpheniramine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10897096/),l,627,34976,DB01114,Chlorphenamine
,24254834,flow rate,"Three analytes were extracted from plasma by liquid-liquid extraction using ethyl acetate and separated on a Kromasil 60-5CN column (3 µm, 2.1 × 150 mm) with mobile phase of acetonitrile-water (containing 0.1% formic acid; 50:50, v/v) at a flow rate of 0.2 mL/min.","Simultaneous quantitative analysis of dextromethorphan, dextrorphan and chlorphenamine in human plasma by liquid chromatography-electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24254834/),[ml] / [min],0.2,41652,DB01114,Chlorphenamine
,11332874,Cmax,"The dose-normalized estimated mean Cmax values were 1.24, 1.43 and 1.21 ng/ml for the peroral tablet and the 1.12 mg and 2.24 mg nasal dose, respectively.",Systemic bioavailability of nasally applied chlorphenamine maleate (0.4% nasal spray) relative to tablets administered perorally. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11332874/),[ng] / [ml],1.24,48613,DB01114,Chlorphenamine
,11332874,Cmax,"The dose-normalized estimated mean Cmax values were 1.24, 1.43 and 1.21 ng/ml for the peroral tablet and the 1.12 mg and 2.24 mg nasal dose, respectively.",Systemic bioavailability of nasally applied chlorphenamine maleate (0.4% nasal spray) relative to tablets administered perorally. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11332874/),[ng] / [ml],1.43,48614,DB01114,Chlorphenamine
,11332874,Cmax,"The dose-normalized estimated mean Cmax values were 1.24, 1.43 and 1.21 ng/ml for the peroral tablet and the 1.12 mg and 2.24 mg nasal dose, respectively.",Systemic bioavailability of nasally applied chlorphenamine maleate (0.4% nasal spray) relative to tablets administered perorally. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11332874/),[ng] / [ml],1.21,48615,DB01114,Chlorphenamine
,11332874,AUC(0-infinity),"The dose-normalized estimated mean AUC(0-infinity) values were 25.91, 26.44 and 25.56 ng x h/ml for the tablet and the 1.12 and 2.24 mg nasal dose, respectively.",Systemic bioavailability of nasally applied chlorphenamine maleate (0.4% nasal spray) relative to tablets administered perorally. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11332874/),[h·ng] / [ml],25.91,48616,DB01114,Chlorphenamine
,11332874,AUC(0-infinity),"The dose-normalized estimated mean AUC(0-infinity) values were 25.91, 26.44 and 25.56 ng x h/ml for the tablet and the 1.12 and 2.24 mg nasal dose, respectively.",Systemic bioavailability of nasally applied chlorphenamine maleate (0.4% nasal spray) relative to tablets administered perorally. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11332874/),[h·ng] / [ml],26.44,48617,DB01114,Chlorphenamine
,11332874,AUC(0-infinity),"The dose-normalized estimated mean AUC(0-infinity) values were 25.91, 26.44 and 25.56 ng x h/ml for the tablet and the 1.12 and 2.24 mg nasal dose, respectively.",Systemic bioavailability of nasally applied chlorphenamine maleate (0.4% nasal spray) relative to tablets administered perorally. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11332874/),[h·ng] / [ml],25.56,48618,DB01114,Chlorphenamine
,3604802,ED50,"The ED50 value for muricidal suppression was about 7.1 mg/kg (95% confidence limits, 5.4-9.3 mg/kg).",Effect of chlorpheniramine on muricide induced by thiamine deficiency: pharmacokinetic and behavioral studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3604802/),[mg] / [kg],7.1,50881,DB01114,Chlorphenamine
,3604802,maximum effect,The maximum effect of muricidal suppression lasted for 1-2 hr after oral dosage (10 mg/kg).,Effect of chlorpheniramine on muricide induced by thiamine deficiency: pharmacokinetic and behavioral studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3604802/),h,1-2,50882,DB01114,Chlorphenamine
,528601,flow-rate,A mobile phase 20% acetonitrile in 0.0075 M phosphate buffer at a flow-rate of 2 ml/min was used for the assays of plasma and saliva samples.,"Chlorpheniramine. I. Rapid quantitative analysis of chlorpheniramine in plasma, saliva and urine by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/528601/),[ml] / [min],2,56120,DB01114,Chlorphenamine
less,528601,retention volumes,The drug and internal standard were eluted at retention volumes of less than 17 ml.,"Chlorpheniramine. I. Rapid quantitative analysis of chlorpheniramine in plasma, saliva and urine by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/528601/),ml,17,56121,DB01114,Chlorphenamine
above,29024852,extraction recoveries,The extraction recoveries of two enantiomers were both above 72.5%.,The cation-selective exhaustive injection and sweeping capillary electrophoresis method for the analysis of chlorpheniramine enantiomers in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29024852/),%,72.5,64512,DB01114,Chlorphenamine
,7106172,terminal half-lives (t 1/1),"In 5 mg (maleate) i.v. bolus studies in 2 subjects, plasma CPM levels were fitted to triexponential equations with terminal half-lives (t 1/1) of 23 and 22 h and area of 3.6 and 3.21/kg, respectively.",Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106172/),h,23,67358,DB01114,Chlorphenamine
,7106172,terminal half-lives (t 1/1),"In 5 mg (maleate) i.v. bolus studies in 2 subjects, plasma CPM levels were fitted to triexponential equations with terminal half-lives (t 1/1) of 23 and 22 h and area of 3.6 and 3.21/kg, respectively.",Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106172/),h,22,67359,DB01114,Chlorphenamine
,7106172,area,"In 5 mg (maleate) i.v. bolus studies in 2 subjects, plasma CPM levels were fitted to triexponential equations with terminal half-lives (t 1/1) of 23 and 22 h and area of 3.6 and 3.21/kg, respectively.",Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106172/),1/[kg],3.6,67360,DB01114,Chlorphenamine
,7106172,area,"In 5 mg (maleate) i.v. bolus studies in 2 subjects, plasma CPM levels were fitted to triexponential equations with terminal half-lives (t 1/1) of 23 and 22 h and area of 3.6 and 3.21/kg, respectively.",Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106172/),1/[kg],3.21,67361,DB01114,Chlorphenamine
,7106172,hepatic blood extraction ratios,"Intravenous data predicted hepatic blood extraction ratios for the 2 subjects to be 0.06 and 0,07, respectively.",Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106172/),,0.06,67362,DB01114,Chlorphenamine
,7106172,hepatic blood extraction ratios,"Intravenous data predicted hepatic blood extraction ratios for the 2 subjects to be 0.06 and 0,07, respectively.",Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106172/),,"0,07",67363,DB01114,Chlorphenamine
,7106172,Absolute bioavailability,"Absolute bioavailability from oral solution (10 mg) was 59 and 34%, and from tablets (8 mg) 44 and 25%, respectively, indicating extensive gut first-pass metabolism.",Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106172/),%,59,67364,DB01114,Chlorphenamine
,7106172,Absolute bioavailability,"Absolute bioavailability from oral solution (10 mg) was 59 and 34%, and from tablets (8 mg) 44 and 25%, respectively, indicating extensive gut first-pass metabolism.",Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106172/),%,34,67365,DB01114,Chlorphenamine
,7106172,Absolute bioavailability,"Absolute bioavailability from oral solution (10 mg) was 59 and 34%, and from tablets (8 mg) 44 and 25%, respectively, indicating extensive gut first-pass metabolism.",Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106172/),%,44,67366,DB01114,Chlorphenamine
,7106172,Absolute bioavailability,"Absolute bioavailability from oral solution (10 mg) was 59 and 34%, and from tablets (8 mg) 44 and 25%, respectively, indicating extensive gut first-pass metabolism.",Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106172/),%,25,67367,DB01114,Chlorphenamine
,7106172,t 1/2,Mean t 1/2 from 7 oral fasting studies in 5 subjects was 28 h (19-43 h).,Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106172/),h,28,67368,DB01114,Chlorphenamine
,7106172,absorption lag time,"Mean absorption lag time was 0.7 h (0.4-1.3 h), and mean peak time was 2.8 h (2-4 h).",Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106172/),h,0.7,67369,DB01114,Chlorphenamine
,7106172,peak time,"Mean absorption lag time was 0.7 h (0.4-1.3 h), and mean peak time was 2.8 h (2-4 h).",Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106172/),h,2.8,67370,DB01114,Chlorphenamine
,7106172,accumulation ratios,Estimated accumulation ratios vary from 4.1 to 9.4 (mean 6.5).,Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106172/),,6.5,67371,DB01114,Chlorphenamine
,16671554,flow rate,"The analytes and the internal standard, diphenhydramine, were isolated from plasma by protein precipitation with methanol, then chromatographied on a Zorbax SB-C18 column (150 mm x 4.6 mm ID) using a mobile phase consisted of methanol-water-formic acid (80: 20: 0.5, v/v), at a flow rate of 0.5 mL x min(-1).",[Simultaneous determination of ephedrine and chlorpheniramine in human plasma by a highly sensitive liquid chromatography-tandem mass spectrometric method]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671554/),[ml] / [min],0.5,67438,DB01114,Chlorphenamine
,17613029,flow rate,"Ethylcellulose with di-n-butyl-phthalate in ethanol and methylene chloride mixture for the coating of drug resinate beads was performed in Glatt fluidized bed coater, where the coating solution flow rate was 8-12 g/min, the inlet air temperature was 50-60 degrees C, the outlet air temperature was 32-38 degrees C, the atomizing air pressure was 2.0 bar and the fluidized air pressure was adjusted as required.",Preparation of codeine-resinate and chlorpheniramine-resinate sustained-release suspension and its pharmacokinetic evaluation in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17613029/),[g] / [min],8-12,68225,DB01114,Chlorphenamine
,17613029,relative bioavailability,"The results showed that the CCSS had the longer value of Tmax and the lower value of Cmax, which meant an obviously sustained release effect, and its relative bioavailability of codeine and chlorpheniramine were (103.6 +/- 14.6)% and (98.1 +/- 10.3)%, respectively, compared with the reference preparation.",Preparation of codeine-resinate and chlorpheniramine-resinate sustained-release suspension and its pharmacokinetic evaluation in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17613029/),%,103.6,68226,DB01114,Chlorphenamine
,17613029,relative bioavailability,"The results showed that the CCSS had the longer value of Tmax and the lower value of Cmax, which meant an obviously sustained release effect, and its relative bioavailability of codeine and chlorpheniramine were (103.6 +/- 14.6)% and (98.1 +/- 10.3)%, respectively, compared with the reference preparation.",Preparation of codeine-resinate and chlorpheniramine-resinate sustained-release suspension and its pharmacokinetic evaluation in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17613029/),%,98.1,68227,DB01114,Chlorphenamine
,6737232,elimination half-life,"In these children, chlorpheniramine had a mean elimination half-life of 13.1 +/- 6.6 h, a mean clearance rate of 7.23 +/- 3.16 mL/min/kg, and a mean apparent volume of distribution of 7.0 +/- 2.8 L/kg.",Urinary excretion of chlorpheniramine and its metabolites in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737232/),h,13.1,69400,DB01114,Chlorphenamine
,6737232,clearance rate,"In these children, chlorpheniramine had a mean elimination half-life of 13.1 +/- 6.6 h, a mean clearance rate of 7.23 +/- 3.16 mL/min/kg, and a mean apparent volume of distribution of 7.0 +/- 2.8 L/kg.",Urinary excretion of chlorpheniramine and its metabolites in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737232/),[ml] / [kg·min],7.23,69401,DB01114,Chlorphenamine
,6737232,apparent volume of distribution,"In these children, chlorpheniramine had a mean elimination half-life of 13.1 +/- 6.6 h, a mean clearance rate of 7.23 +/- 3.16 mL/min/kg, and a mean apparent volume of distribution of 7.0 +/- 2.8 L/kg.",Urinary excretion of chlorpheniramine and its metabolites in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737232/),[l] / [kg],7.0,69402,DB01114,Chlorphenamine
,6737232,recovery,"Over 48 h, the recovery in urine was as follows: chlorpheniramine, 11.3 +/- 6.7%; demethylchlorpheniramine , 23.3 +/- 11.1%; and didemethylchlorpheniramine , 9.6 +/- 9.4%.",Urinary excretion of chlorpheniramine and its metabolites in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737232/),%,11.3,69403,DB01114,Chlorphenamine
,6737232,recovery,"Over 48 h, the recovery in urine was as follows: chlorpheniramine, 11.3 +/- 6.7%; demethylchlorpheniramine , 23.3 +/- 11.1%; and didemethylchlorpheniramine , 9.6 +/- 9.4%.",Urinary excretion of chlorpheniramine and its metabolites in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737232/),%,23.3,69404,DB01114,Chlorphenamine
,6737232,recovery,"Over 48 h, the recovery in urine was as follows: chlorpheniramine, 11.3 +/- 6.7%; demethylchlorpheniramine , 23.3 +/- 11.1%; and didemethylchlorpheniramine , 9.6 +/- 9.4%.",Urinary excretion of chlorpheniramine and its metabolites in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737232/),%,9.6,69405,DB01114,Chlorphenamine
,6737232,Urine flow rate,"Urine flow rate and urine pH were uncontrolled and ranged from 2.2 to 113.3 mL/h and 5.1-7.9, respectively, over the 48-h period.",Urinary excretion of chlorpheniramine and its metabolites in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737232/),[ml] / [h],2.2 to 113.3,69406,DB01114,Chlorphenamine
,6737232,urine pH,"Urine flow rate and urine pH were uncontrolled and ranged from 2.2 to 113.3 mL/h and 5.1-7.9, respectively, over the 48-h period.",Urinary excretion of chlorpheniramine and its metabolites in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737232/),,5.1-7.9,69407,DB01114,Chlorphenamine
,18186973,bio-availability,"The bio-availability of CQ was also significantly increased in the presence of CP, with the mean value for the area under the curve, of erythrocytic concentration v. time, increasing from 99,921 to 214,516 ng/ml.h (P=0.001).",Comparative study of interactions between chloroquine and chlorpheniramine or promethazine in healthy volunteers: a potential combination-therapy phenomenon for resuscitating chloroquine for malaria treatment in Africa. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18186973/),[ng] / [h·ml],"99,921",69764,DB01114,Chlorphenamine
,18186973,bio-availability,"The bio-availability of CQ was also significantly increased in the presence of CP, with the mean value for the area under the curve, of erythrocytic concentration v. time, increasing from 99,921 to 214,516 ng/ml.h (P=0.001).",Comparative study of interactions between chloroquine and chlorpheniramine or promethazine in healthy volunteers: a potential combination-therapy phenomenon for resuscitating chloroquine for malaria treatment in Africa. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18186973/),[ng] / [h·ml],"214,516",69765,DB01114,Chlorphenamine
,18186973,area under the curve,"The bio-availability of CQ was also significantly increased in the presence of CP, with the mean value for the area under the curve, of erythrocytic concentration v. time, increasing from 99,921 to 214,516 ng/ml.h (P=0.001).",Comparative study of interactions between chloroquine and chlorpheniramine or promethazine in healthy volunteers: a potential combination-therapy phenomenon for resuscitating chloroquine for malaria treatment in Africa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18186973/),[ng] / [h·ml],"99,921",69766,DB01114,Chlorphenamine
,18186973,area under the curve,"The bio-availability of CQ was also significantly increased in the presence of CP, with the mean value for the area under the curve, of erythrocytic concentration v. time, increasing from 99,921 to 214,516 ng/ml.h (P=0.001).",Comparative study of interactions between chloroquine and chlorpheniramine or promethazine in healthy volunteers: a potential combination-therapy phenomenon for resuscitating chloroquine for malaria treatment in Africa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18186973/),[ng] / [h·ml],"214,516",69767,DB01114,Chlorphenamine
,18186973,half-life,"The mean half-life of CQ in the erythrocytes also increased when CP was used, from 51 to 100 h, but this change was not statistically significant (P=0.83).",Comparative study of interactions between chloroquine and chlorpheniramine or promethazine in healthy volunteers: a potential combination-therapy phenomenon for resuscitating chloroquine for malaria treatment in Africa. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18186973/),h,51,69768,DB01114,Chlorphenamine
,18186973,half-life,"The mean half-life of CQ in the erythrocytes also increased when CP was used, from 51 to 100 h, but this change was not statistically significant (P=0.83).",Comparative study of interactions between chloroquine and chlorpheniramine or promethazine in healthy volunteers: a potential combination-therapy phenomenon for resuscitating chloroquine for malaria treatment in Africa. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18186973/),h,100,69769,DB01114,Chlorphenamine
,7104467,plasma elimination half-lives,The mean plasma elimination half-lives of the various dosage forms were in the range 24.5-25.4 h.,Blood levels following multiple oral dosing of chlorpheniramine conventional and controlled release preparations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104467/),h,24.5-25.4,70323,DB01114,Chlorphenamine
,7104467,half-life,"Since the half-life of chlorpheniramine is approximately 1 day, therapeutic management may possibly be gained with dosing the patient once daily with a controlled release product or twice daily with a conventional tablet.",Blood levels following multiple oral dosing of chlorpheniramine conventional and controlled release preparations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104467/),d,1,70324,DB01114,Chlorphenamine
,7341757,oral absolute bioavailabilities,"The oral absolute bioavailabilities of chloropheniramine (CPM) in four rabbits (New Zealand White, male, mean wt. 3.71 kg), averaged 0.06 +/- 0.03, 0.11 +/- 0.08, and 0.09 +/- 0.01 following a 3, 10.5, and 21 mg/kg dose, respectively.",Oral absorption and presystemic first-pass effect of chlorpheniramine in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341757/),,0.06,74932,DB01114,Chlorphenamine
,7341757,oral absolute bioavailabilities,"The oral absolute bioavailabilities of chloropheniramine (CPM) in four rabbits (New Zealand White, male, mean wt. 3.71 kg), averaged 0.06 +/- 0.03, 0.11 +/- 0.08, and 0.09 +/- 0.01 following a 3, 10.5, and 21 mg/kg dose, respectively.",Oral absorption and presystemic first-pass effect of chlorpheniramine in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341757/),,0.11,74933,DB01114,Chlorphenamine
,7341757,oral absolute bioavailabilities,"The oral absolute bioavailabilities of chloropheniramine (CPM) in four rabbits (New Zealand White, male, mean wt. 3.71 kg), averaged 0.06 +/- 0.03, 0.11 +/- 0.08, and 0.09 +/- 0.01 following a 3, 10.5, and 21 mg/kg dose, respectively.",Oral absorption and presystemic first-pass effect of chlorpheniramine in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341757/),,0.09,74934,DB01114,Chlorphenamine
,7341757,extraction ratios,"Based on the oral, intraportal vein and i.v. studies, the mean extraction ratios of gut and the liver calculated for these two rabbits averaged 0.58 and 0.76, respectively.",Oral absorption and presystemic first-pass effect of chlorpheniramine in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341757/),,0.58,74935,DB01114,Chlorphenamine
,7341757,extraction ratios,"Based on the oral, intraportal vein and i.v. studies, the mean extraction ratios of gut and the liver calculated for these two rabbits averaged 0.58 and 0.76, respectively.",Oral absorption and presystemic first-pass effect of chlorpheniramine in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341757/),,0.76,74936,DB01114,Chlorphenamine
,7341757,hepatic extraction ratio,The latter value agreed well with the estimated hepatic extraction ratio from the in vitro liver homogenate study (0.89) or from the i.v. studies (0.83).,Oral absorption and presystemic first-pass effect of chlorpheniramine in rabbits. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341757/),,0.89,74937,DB01114,Chlorphenamine
,7341757,hepatic extraction ratio,The latter value agreed well with the estimated hepatic extraction ratio from the in vitro liver homogenate study (0.89) or from the i.v. studies (0.83).,Oral absorption and presystemic first-pass effect of chlorpheniramine in rabbits. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341757/),,0.83,74938,DB01114,Chlorphenamine
,11994058,Cmax,"In extensive metabolizers, mean Cmax was greater (12.55+/-1.51 ng ml-1vs 5.38+/-0.44 ng ml-1) and CLoral was lower (0.49+/-0.08 l h-1 kg-1vs 1.07+/-0.15 l h-1 kg-1) for (S)-(+)- than for (R)-(-)-chlorpheniramine (P<0.005).",The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994058/),[ng] / [ml],12.55,89047,DB01114,Chlorphenamine
,11994058,Cmax,"In extensive metabolizers, mean Cmax was greater (12.55+/-1.51 ng ml-1vs 5.38+/-0.44 ng ml-1) and CLoral was lower (0.49+/-0.08 l h-1 kg-1vs 1.07+/-0.15 l h-1 kg-1) for (S)-(+)- than for (R)-(-)-chlorpheniramine (P<0.005).",The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994058/),[ng] / [ml],5.38,89048,DB01114,Chlorphenamine
,11994058,CLoral,"In extensive metabolizers, mean Cmax was greater (12.55+/-1.51 ng ml-1vs 5.38+/-0.44 ng ml-1) and CLoral was lower (0.49+/-0.08 l h-1 kg-1vs 1.07+/-0.15 l h-1 kg-1) for (S)-(+)- than for (R)-(-)-chlorpheniramine (P<0.005).",The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994058/),[l] / [h·kg],0.49,89049,DB01114,Chlorphenamine
,11994058,CLoral,"In extensive metabolizers, mean Cmax was greater (12.55+/-1.51 ng ml-1vs 5.38+/-0.44 ng ml-1) and CLoral was lower (0.49+/-0.08 l h-1 kg-1vs 1.07+/-0.15 l h-1 kg-1) for (S)-(+)- than for (R)-(-)-chlorpheniramine (P<0.005).",The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994058/),[l] / [h·kg],1.07,89050,DB01114,Chlorphenamine
,11994058,Cmax,"For (S)-(+)-chlorpheniramine, administration of quinidine, an inhibitor of CYP2D6, resulted in an increase in Cmax to 13.94+/-1.51 (P<0.01), a reduction in CLoral to 0.22+/-0.03 l h-1 kg-1 (P<0.01), and a prolongation of elimination half-life from 18.0+/-2.0 h to 29.3+/-2.0 h (P<0.001).",The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994058/),,13.94,89051,DB01114,Chlorphenamine
,11994058,CLoral,"For (S)-(+)-chlorpheniramine, administration of quinidine, an inhibitor of CYP2D6, resulted in an increase in Cmax to 13.94+/-1.51 (P<0.01), a reduction in CLoral to 0.22+/-0.03 l h-1 kg-1 (P<0.01), and a prolongation of elimination half-life from 18.0+/-2.0 h to 29.3+/-2.0 h (P<0.001).",The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994058/),[l] / [h·kg],0.22,89052,DB01114,Chlorphenamine
,11994058,elimination half-life,"For (S)-(+)-chlorpheniramine, administration of quinidine, an inhibitor of CYP2D6, resulted in an increase in Cmax to 13.94+/-1.51 (P<0.01), a reduction in CLoral to 0.22+/-0.03 l h-1 kg-1 (P<0.01), and a prolongation of elimination half-life from 18.0+/-2.0 h to 29.3+/-2.0 h (P<0.001).",The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994058/),h,18.0,89053,DB01114,Chlorphenamine
,11994058,elimination half-life,"For (S)-(+)-chlorpheniramine, administration of quinidine, an inhibitor of CYP2D6, resulted in an increase in Cmax to 13.94+/-1.51 (P<0.01), a reduction in CLoral to 0.22+/-0.03 l h-1 kg-1 (P<0.01), and a prolongation of elimination half-life from 18.0+/-2.0 h to 29.3+/-2.0 h (P<0.001).",The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994058/),h,29.3,89054,DB01114,Chlorphenamine
,11994058,CLoral,Administration of quinidine decreased CLoral for (R)-(-)-chlorpheniramine to 0.60+/-0.10 l h-1 kg-1 (P<0.005).,The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994058/),[l] / [h·kg],0.60,89055,DB01114,Chlorphenamine
,2866055,Bioavailability,"Bioavailability has not been extensively studied, but is about 0.34 for chlorpheniramine, 0.40 to 0.60 for diphenhydramine, and about 0.25 for promethazine.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),,0.34,96056,DB01114,Chlorphenamine
,2866055,Bioavailability,"Bioavailability has not been extensively studied, but is about 0.34 for chlorpheniramine, 0.40 to 0.60 for diphenhydramine, and about 0.25 for promethazine.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),,0.40 to 0.60,96057,DB01114,Chlorphenamine
,2866055,Bioavailability,"Bioavailability has not been extensively studied, but is about 0.34 for chlorpheniramine, 0.40 to 0.60 for diphenhydramine, and about 0.25 for promethazine.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),,0.25,96058,DB01114,Chlorphenamine
,2866055,Total body clearance,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),[ml] / [kg·min],5 to 12,96059,DB01114,Chlorphenamine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,3,96060,DB01114,Chlorphenamine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),d,18,96061,DB01114,Chlorphenamine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,4,96062,DB01114,Chlorphenamine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,10 to 14,96063,DB01114,Chlorphenamine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,14 to 25,96064,DB01114,Chlorphenamine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,20,96065,DB01114,Chlorphenamine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,25,96066,DB01114,Chlorphenamine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),d,18 to 20,96067,DB01114,Chlorphenamine
excess,2866055,apparent volumes of distribution,They also have relatively large apparent volumes of distribution in excess of 4 L/kg.,Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),[l] / [kg],4,96068,DB01114,Chlorphenamine
,2866055,elimination half-life,"In patients with alcohol-related liver disease, the elimination half-life of diphenhydramine was increased from 9 to 15 hours, while in patients with chronic renal disease that of chlorpheniramine was very greatly prolonged.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,9 to 15,96069,DB01114,Chlorphenamine
,2692938,half-life,Terfenadine exhibits a bimodal elimination phase (slow component +/- 22 hours) and astemizole has an active metabolite with a half-life of 12 days.,Anti-allergy and anti-asthma drugs. Disposition in infancy and childhood. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2692938/),d,12,96936,DB01114,Chlorphenamine
,2692938,half-lives,"The half-lives of most other antihistamines lie in the 4- to 8-hour range (except chlorpheniramine, which has a longer half-life).",Anti-allergy and anti-asthma drugs. Disposition in infancy and childhood. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2692938/),h,4- to 8-,96937,DB01114,Chlorphenamine
,8688987,area under the curve up to the last concentration (AUC0-t),"The geometric mean for the area under the curve up to the last concentration (AUC0-t), to infinity (AUC0-oo) and the maximum concentration (Cp max) were 316.5, 315 + 439.8, 431.2 (ngh/ml) and 22, 20.5 (ug/ml) for the test (T) and reference (R) formulations, respectively.",Bioequivalence and pharmacokinetics of chlorpheneramine in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688987/),[ngh] / [ml],"316.5,",109079,DB01114,Chlorphenamine
,8688987,to infinity (AUC0-oo),"The geometric mean for the area under the curve up to the last concentration (AUC0-t), to infinity (AUC0-oo) and the maximum concentration (Cp max) were 316.5, 315 + 439.8, 431.2 (ngh/ml) and 22, 20.5 (ug/ml) for the test (T) and reference (R) formulations, respectively.",Bioequivalence and pharmacokinetics of chlorpheneramine in healthy human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688987/),[ngh] / [ml],315,109080,DB01114,Chlorphenamine
,8688987,to infinity (AUC0-oo),"The geometric mean for the area under the curve up to the last concentration (AUC0-t), to infinity (AUC0-oo) and the maximum concentration (Cp max) were 316.5, 315 + 439.8, 431.2 (ngh/ml) and 22, 20.5 (ug/ml) for the test (T) and reference (R) formulations, respectively.",Bioequivalence and pharmacokinetics of chlorpheneramine in healthy human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688987/),[ngh] / [ml],431.2,109081,DB01114,Chlorphenamine
,8688987,maximum concentration (Cp max),"The geometric mean for the area under the curve up to the last concentration (AUC0-t), to infinity (AUC0-oo) and the maximum concentration (Cp max) were 316.5, 315 + 439.8, 431.2 (ngh/ml) and 22, 20.5 (ug/ml) for the test (T) and reference (R) formulations, respectively.",Bioequivalence and pharmacokinetics of chlorpheneramine in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688987/),[ug] / [ml],"22, 20.5",109082,DB01114,Chlorphenamine
,8688987,time to the maximum concentration Tmax,"The mean time to the maximum concentration Tmax (h) were 2.5 and 2.08 for the two formulations respectively and the parametric 90% confidence intervals of the Tmax difference (T-R) were in the range of -0.26-1.14 h, with point estimate of 0.44 h.",Bioequivalence and pharmacokinetics of chlorpheneramine in healthy human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688987/),h,2.5,109083,DB01114,Chlorphenamine
,8688987,time to the maximum concentration Tmax,"The mean time to the maximum concentration Tmax (h) were 2.5 and 2.08 for the two formulations respectively and the parametric 90% confidence intervals of the Tmax difference (T-R) were in the range of -0.26-1.14 h, with point estimate of 0.44 h.",Bioequivalence and pharmacokinetics of chlorpheneramine in healthy human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688987/),h,2.08,109084,DB01114,Chlorphenamine
,10492767,parasite clearance time,Treatment with CQ-CP combination resulted in a shorter parasite clearance time (2.0 +/- 0.5 days) and a higher cure rate (87.5%) compared to treatment with CQ alone (3.5 +/- 0.5 days; 66.7%).,Effect of chlorpheniramine on the pharmacokinetics of and response to chloroquine of Nigerian children with falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492767/),d,2.0,109541,DB01114,Chlorphenamine
,10492767,cure rate,Treatment with CQ-CP combination resulted in a shorter parasite clearance time (2.0 +/- 0.5 days) and a higher cure rate (87.5%) compared to treatment with CQ alone (3.5 +/- 0.5 days; 66.7%).,Effect of chlorpheniramine on the pharmacokinetics of and response to chloroquine of Nigerian children with falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492767/),d,3.5,109542,DB01114,Chlorphenamine
,23489843,terminal half-life,"Following an intravenous (IV) dose of 0.5mg/kg bodyweight (BW), plasma drug disposition was very rapid, with the mean terminal half-life and total body clearance calculated as 2.7h and 0.7 L/h/kg, respectively.",Pharmacokinetics and pharmacodynamics of d-chlorpheniramine following intravenous and oral administration in healthy Thoroughbred horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23489843/),h,2.7,122349,DB01114,Chlorphenamine
,23489843,total body clearance,"Following an intravenous (IV) dose of 0.5mg/kg bodyweight (BW), plasma drug disposition was very rapid, with the mean terminal half-life and total body clearance calculated as 2.7h and 0.7 L/h/kg, respectively.",Pharmacokinetics and pharmacodynamics of d-chlorpheniramine following intravenous and oral administration in healthy Thoroughbred horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23489843/),[l] / [h·kg],0.7,122350,DB01114,Chlorphenamine
,23489843,maximal inhibition,"The observed maximal inhibition of wheal formation following IV doses of 0.1 and 0.5mg/kg BW were 37.8% and 60.6% at 0.5h, respectively.",Pharmacokinetics and pharmacodynamics of d-chlorpheniramine following intravenous and oral administration in healthy Thoroughbred horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23489843/),%,37.8,122351,DB01114,Chlorphenamine
,23489843,maximal inhibition,"The observed maximal inhibition of wheal formation following IV doses of 0.1 and 0.5mg/kg BW were 37.8% and 60.6% at 0.5h, respectively.",Pharmacokinetics and pharmacodynamics of d-chlorpheniramine following intravenous and oral administration in healthy Thoroughbred horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23489843/),%,60.6,122352,DB01114,Chlorphenamine
,23489843,bioavailability,"Oral administration of CPM (0.5mg/kg BW) resulted in a bioavailability of 38%, which induced a peak plasma drug concentration at 1h and a maximal inhibition of wheal formation (39%) at 2h.",Pharmacokinetics and pharmacodynamics of d-chlorpheniramine following intravenous and oral administration in healthy Thoroughbred horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23489843/),%,38,122353,DB01114,Chlorphenamine
,23489843,maximal in,"Oral administration of CPM (0.5mg/kg BW) resulted in a bioavailability of 38%, which induced a peak plasma drug concentration at 1h and a maximal inhibition of wheal formation (39%) at 2h.",Pharmacokinetics and pharmacodynamics of d-chlorpheniramine following intravenous and oral administration in healthy Thoroughbred horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23489843/),,39,122354,DB01114,Chlorphenamine
,7069073,half-life,"In 11 patients with allergic rhinitis, ages 6 to 16 yr, we found a mean serum chlorpheniramine half-life of 13.1 +/- 6.3 hr, a mean volume of distribution of 7.0 +/- 2.8 L/kg, and a mean clearance rate of 7.2 +/- 3.2 ml/min/kg.",Pharmacokinetics and efficacy of chlorpheniramine in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7069073/),h,13.1,131421,DB01114,Chlorphenamine
,7069073,volume of distribution,"In 11 patients with allergic rhinitis, ages 6 to 16 yr, we found a mean serum chlorpheniramine half-life of 13.1 +/- 6.3 hr, a mean volume of distribution of 7.0 +/- 2.8 L/kg, and a mean clearance rate of 7.2 +/- 3.2 ml/min/kg.",Pharmacokinetics and efficacy of chlorpheniramine in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7069073/),[l] / [kg],7.0,131422,DB01114,Chlorphenamine
,7069073,clearance rate,"In 11 patients with allergic rhinitis, ages 6 to 16 yr, we found a mean serum chlorpheniramine half-life of 13.1 +/- 6.3 hr, a mean volume of distribution of 7.0 +/- 2.8 L/kg, and a mean clearance rate of 7.2 +/- 3.2 ml/min/kg.",Pharmacokinetics and efficacy of chlorpheniramine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7069073/),[ml] / [kg·min],7.2,131423,DB01114,Chlorphenamine
,512844,distribution phase half-life,"The mean distribution phase half-life was 12.5 min, and the mean apparent volume of distribution, Vdb, was 525% of the body weight in four dogs with normal hematocrits.",Chlorpheniramine. Effect of the first-pass metabolism on the oral bioavailability in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512844/),min,12.5,152996,DB01114,Chlorphenamine
,512844,half-life of elimination,The mean half-life of elimination was 1.7 hr.,Chlorpheniramine. Effect of the first-pass metabolism on the oral bioavailability in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/512844/),h,1.7,152997,DB01114,Chlorphenamine
,512844,bioavailability,"At 50-mg dose, in one of the four dogs studied, no measurable plasma levels of chlorpheniramine were obtained, and the average bioavailability was only 9.4%.",Chlorpheniramine. Effect of the first-pass metabolism on the oral bioavailability in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512844/),%,9.4,152998,DB01114,Chlorphenamine
,512844,availability,The average availability in four dogs at 200-mg dose was 39.4%.,Chlorpheniramine. Effect of the first-pass metabolism on the oral bioavailability in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512844/),%,39.4,152999,DB01114,Chlorphenamine
,2892445,serum elimination half-life,"The serum elimination half-life values of these agents are variable: a few hours for terfenadine and triprolidine; about 9 hours for cetirizine, azatadine, and loratadine; from 20 to 25 hours for hydroxyzine, chlorpheniramine, and brompheniramine; and from 5 to 14 days for astemizole.",The comparative pharmacokinetics of H1-receptor antagonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),h,few,153583,DB01114,Chlorphenamine
,2892445,serum elimination half-life,"The serum elimination half-life values of these agents are variable: a few hours for terfenadine and triprolidine; about 9 hours for cetirizine, azatadine, and loratadine; from 20 to 25 hours for hydroxyzine, chlorpheniramine, and brompheniramine; and from 5 to 14 days for astemizole.",The comparative pharmacokinetics of H1-receptor antagonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),h,9,153584,DB01114,Chlorphenamine
,2892445,serum elimination half-life,"The serum elimination half-life values of these agents are variable: a few hours for terfenadine and triprolidine; about 9 hours for cetirizine, azatadine, and loratadine; from 20 to 25 hours for hydroxyzine, chlorpheniramine, and brompheniramine; and from 5 to 14 days for astemizole.",The comparative pharmacokinetics of H1-receptor antagonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),h,20 to 25,153585,DB01114,Chlorphenamine
,2892445,serum elimination half-life,"The serum elimination half-life values of these agents are variable: a few hours for terfenadine and triprolidine; about 9 hours for cetirizine, azatadine, and loratadine; from 20 to 25 hours for hydroxyzine, chlorpheniramine, and brompheniramine; and from 5 to 14 days for astemizole.",The comparative pharmacokinetics of H1-receptor antagonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),d,5 to 14,153586,DB01114,Chlorphenamine
,2892445,apparent volumes of distribution,"Regardless of the age of patients, for most of the H1-receptor antagonists the apparent volumes of distribution and total body clearances appear to be large (3.4 to 18.5 L/kg and 4.4 to 32.1 mL/min/kg, respectively).",The comparative pharmacokinetics of H1-receptor antagonists. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),[l] / [kg],3.4 to 18.5,153587,DB01114,Chlorphenamine
,2892445,total body clearances,"Regardless of the age of patients, for most of the H1-receptor antagonists the apparent volumes of distribution and total body clearances appear to be large (3.4 to 18.5 L/kg and 4.4 to 32.1 mL/min/kg, respectively).",The comparative pharmacokinetics of H1-receptor antagonists. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),[ml] / [kg·min],4.4 to 32.1,153588,DB01114,Chlorphenamine
,8667473,Initial extraction ratio,Initial extraction ratio of the hemoperfusion cartridge was 0.54 with plasma clearance of 54.5 mL/min.,Delayed peak serum valproic acid in massive divalproex overdose--treatment with charcoal hemoperfusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8667473/),,0.54,169443,DB01114,Chlorphenamine
,8667473,plasma clearance,Initial extraction ratio of the hemoperfusion cartridge was 0.54 with plasma clearance of 54.5 mL/min.,Delayed peak serum valproic acid in massive divalproex overdose--treatment with charcoal hemoperfusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8667473/),[ml] / [min],54.5,169444,DB01114,Chlorphenamine
,8667473,elimination half-life,Valproic acid elimination half-life was 3 h during the 190 min hemoperfusion cycle.,Delayed peak serum valproic acid in massive divalproex overdose--treatment with charcoal hemoperfusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8667473/),h,3,169445,DB01114,Chlorphenamine
,8667473,elimination half-life,Posthemoperfusion elimination half-life was 4.8 h with continued multiple-dose activated charcoal dosing.,Delayed peak serum valproic acid in massive divalproex overdose--treatment with charcoal hemoperfusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8667473/),h,4.8,169446,DB01114,Chlorphenamine
,21294141,flow rate of the mobile phase,"The flow rate of the mobile phase was 200 μL/min and the retention times of sibutramine, M1, M2 and internal standard (chlorpheniramine) were 1.5, 1.4, 1.3 and 0.9 min, respectively.",Simultaneous determination of sibutramine and its active metabolites in human plasma by LC-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21294141/),[μl] / [min],200,174499,DB01114,Chlorphenamine
,21294141,retention times,"The flow rate of the mobile phase was 200 μL/min and the retention times of sibutramine, M1, M2 and internal standard (chlorpheniramine) were 1.5, 1.4, 1.3 and 0.9 min, respectively.",Simultaneous determination of sibutramine and its active metabolites in human plasma by LC-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21294141/),min,1.5,174500,DB01114,Chlorphenamine
,21294141,retention times,"The flow rate of the mobile phase was 200 μL/min and the retention times of sibutramine, M1, M2 and internal standard (chlorpheniramine) were 1.5, 1.4, 1.3 and 0.9 min, respectively.",Simultaneous determination of sibutramine and its active metabolites in human plasma by LC-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21294141/),min,1.4,174501,DB01114,Chlorphenamine
,21294141,retention times,"The flow rate of the mobile phase was 200 μL/min and the retention times of sibutramine, M1, M2 and internal standard (chlorpheniramine) were 1.5, 1.4, 1.3 and 0.9 min, respectively.",Simultaneous determination of sibutramine and its active metabolites in human plasma by LC-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21294141/),min,1.3,174502,DB01114,Chlorphenamine
,21294141,retention times,"The flow rate of the mobile phase was 200 μL/min and the retention times of sibutramine, M1, M2 and internal standard (chlorpheniramine) were 1.5, 1.4, 1.3 and 0.9 min, respectively.",Simultaneous determination of sibutramine and its active metabolites in human plasma by LC-MS/MS and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21294141/),min,0.9,174503,DB01114,Chlorphenamine
,25417559,flow rate,"Chromatographic separation was performed by pumping the mobile phase containing acetonitrile, water and formic acid (89.2:11.7:0.1) for 2.0 min at a flow rate of 0.25 μL/min into a Hypersil-Gold C18 column, 20 × 2.0 mm (1.9 µm) from Thermoscientific, New York, USA.","Development and validation of a sensitive UHPLC-MS/MS method for the simultaneous analysis of tramadol, dextromethorphan chlorpheniramine and their major metabolites in human plasma in forensic context: application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25417559/),[μl] / [min],0.25,178279,DB01114,Chlorphenamine
,20735301,oral bioavailability,"Our study aimed to develop a nasal gel formulation for an antihistaminic drug, Chlorpheniramine maleate (CPM), which suffers from poor oral bioavailability (25-45%) due to its first-pass metabolism in the liver.",Formulation and stability study of chlorpheniramine maleate nasal gel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20735301/),%,25-45,182174,DB01114,Chlorphenamine
,17558437,"partition coefficient, K(p)","The concentration-time profile of levocetirizine indicated lower levels (partition coefficient, K(p)=0.06-0.08), higher t(max) (2-4 h vs 1-1.5 h) and longer terminal half-life (4-5.6 h vs 2.1-2.8 h) in brain than plasma.","Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17558437/),,0.06-0.08,193565,DB01114,Chlorphenamine
,17558437,t(max),"The concentration-time profile of levocetirizine indicated lower levels (partition coefficient, K(p)=0.06-0.08), higher t(max) (2-4 h vs 1-1.5 h) and longer terminal half-life (4-5.6 h vs 2.1-2.8 h) in brain than plasma.","Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17558437/),h,2-4,193566,DB01114,Chlorphenamine
,17558437,t(max),"The concentration-time profile of levocetirizine indicated lower levels (partition coefficient, K(p)=0.06-0.08), higher t(max) (2-4 h vs 1-1.5 h) and longer terminal half-life (4-5.6 h vs 2.1-2.8 h) in brain than plasma.","Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17558437/),h,1-1.5,193567,DB01114,Chlorphenamine
,17558437,terminal half-life,"The concentration-time profile of levocetirizine indicated lower levels (partition coefficient, K(p)=0.06-0.08), higher t(max) (2-4 h vs 1-1.5 h) and longer terminal half-life (4-5.6 h vs 2.1-2.8 h) in brain than plasma.","Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17558437/),h,4-5.6,193568,DB01114,Chlorphenamine
,17558437,terminal half-life,"The concentration-time profile of levocetirizine indicated lower levels (partition coefficient, K(p)=0.06-0.08), higher t(max) (2-4 h vs 1-1.5 h) and longer terminal half-life (4-5.6 h vs 2.1-2.8 h) in brain than plasma.","Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17558437/),h,2.1-2.8,193569,DB01114,Chlorphenamine
,1350627,half-lives,"In the elimination phase, the concentrations of (+)- and (-)-chlorpheniramine in the plasma declined biexponentially with half-lives of 18.2 and 50.0 min, respectively.",The optical resolution of racemic chlorpheniramine and its stereoselective pharmacokinetics in rat plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1350627/),min,18.2,194418,DB01114,Chlorphenamine
,1350627,half-lives,"In the elimination phase, the concentrations of (+)- and (-)-chlorpheniramine in the plasma declined biexponentially with half-lives of 18.2 and 50.0 min, respectively.",The optical resolution of racemic chlorpheniramine and its stereoselective pharmacokinetics in rat plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1350627/),min,50.0,194419,DB01114,Chlorphenamine
,22119507,flow rate,"Following liquid-liquid extraction, the analytes were separated on a reversed-phase C(18) column (150 mm × 2.0 mm, 3 μm) using formic acid:10 mM ammonium acetate:methanol (0.2:62:38, v/v/v) as mobile phase at a flow rate of 0.2 mL/min and analyzed by a triple-quadrupole mass spectrometer in the selected reaction monitoring (SRM) mode.","Simultaneous determination of codeine, ephedrine, guaiphenesin and chlorpheniramine in beagle dog plasma using high performance liquid chromatography coupled with tandem mass spectrometric detection: application to a bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22119507/),[ml] / [min],0.2,215136,DB01114,Chlorphenamine
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,152.3,224505,DB01114,Chlorphenamine
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,152.3,224506,DB01114,Chlorphenamine
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,195.1,224507,DB01114,Chlorphenamine
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,138.3,224508,DB01114,Chlorphenamine
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,275.2,224509,DB01114,Chlorphenamine
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,230.3,224510,DB01114,Chlorphenamine
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,264.2,224511,DB01114,Chlorphenamine
,10528077,force of detachment,"The force of detachment for the mucoadhesive buccal tablets containing 22 mg of Hakea and either 25 and 40 mg CPM, and 32 mg Hakea and 40 mg CPM increased from 1.64+/-0.47 to 7.32+/-0.34 N, 1.67+/-0.30 to 7.21+/-0.36 N, and 2.93+/-0.73 to 7.92+/-0.60 N, respectively from 5 to 90 min following application to excised intestinal mucosa.","Transmucosal sustained-delivery of chlorpheniramine maleate in rabbits using a novel, natural mucoadhesive gum as an excipient in buccal tablets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10528077/),n,1.64,233459,DB01114,Chlorphenamine
,10528077,force of detachment,"The force of detachment for the mucoadhesive buccal tablets containing 22 mg of Hakea and either 25 and 40 mg CPM, and 32 mg Hakea and 40 mg CPM increased from 1.64+/-0.47 to 7.32+/-0.34 N, 1.67+/-0.30 to 7.21+/-0.36 N, and 2.93+/-0.73 to 7.92+/-0.60 N, respectively from 5 to 90 min following application to excised intestinal mucosa.","Transmucosal sustained-delivery of chlorpheniramine maleate in rabbits using a novel, natural mucoadhesive gum as an excipient in buccal tablets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10528077/),n,7.32,233460,DB01114,Chlorphenamine
,10528077,force of detachment,"The force of detachment for the mucoadhesive buccal tablets containing 22 mg of Hakea and either 25 and 40 mg CPM, and 32 mg Hakea and 40 mg CPM increased from 1.64+/-0.47 to 7.32+/-0.34 N, 1.67+/-0.30 to 7.21+/-0.36 N, and 2.93+/-0.73 to 7.92+/-0.60 N, respectively from 5 to 90 min following application to excised intestinal mucosa.","Transmucosal sustained-delivery of chlorpheniramine maleate in rabbits using a novel, natural mucoadhesive gum as an excipient in buccal tablets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10528077/),n,1.67,233461,DB01114,Chlorphenamine
,10528077,force of detachment,"The force of detachment for the mucoadhesive buccal tablets containing 22 mg of Hakea and either 25 and 40 mg CPM, and 32 mg Hakea and 40 mg CPM increased from 1.64+/-0.47 to 7.32+/-0.34 N, 1.67+/-0.30 to 7.21+/-0.36 N, and 2.93+/-0.73 to 7.92+/-0.60 N, respectively from 5 to 90 min following application to excised intestinal mucosa.","Transmucosal sustained-delivery of chlorpheniramine maleate in rabbits using a novel, natural mucoadhesive gum as an excipient in buccal tablets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10528077/),n,7.21,233462,DB01114,Chlorphenamine
,10528077,force of detachment,"The force of detachment for the mucoadhesive buccal tablets containing 22 mg of Hakea and either 25 and 40 mg CPM, and 32 mg Hakea and 40 mg CPM increased from 1.64+/-0.47 to 7.32+/-0.34 N, 1.67+/-0.30 to 7.21+/-0.36 N, and 2.93+/-0.73 to 7.92+/-0.60 N, respectively from 5 to 90 min following application to excised intestinal mucosa.","Transmucosal sustained-delivery of chlorpheniramine maleate in rabbits using a novel, natural mucoadhesive gum as an excipient in buccal tablets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10528077/),n,2.93,233463,DB01114,Chlorphenamine
,10528077,force of detachment,"The force of detachment for the mucoadhesive buccal tablets containing 22 mg of Hakea and either 25 and 40 mg CPM, and 32 mg Hakea and 40 mg CPM increased from 1.64+/-0.47 to 7.32+/-0.34 N, 1.67+/-0.30 to 7.21+/-0.36 N, and 2.93+/-0.73 to 7.92+/-0.60 N, respectively from 5 to 90 min following application to excised intestinal mucosa.","Transmucosal sustained-delivery of chlorpheniramine maleate in rabbits using a novel, natural mucoadhesive gum as an excipient in buccal tablets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10528077/),n,7.92,233464,DB01114,Chlorphenamine
,32724819,m,"The multiple reaction monitoring (MRM) modes of m/z 238.1→m/z 179.1 for KET, m/z 224.1→m/z 207.1 for NK, and m/z 275→m/z 230 for Chlor-Trimeton (IS) were utilized to conduct a quantitative analysis.",Pharmacokinetic Effects of l-Tetrahydropalmatine on Ketamine in Rat Plasma by Ultraperformance Liquid Chromatography Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32724819/),,238.1,242409,DB01114,Chlorphenamine
more,32724819,extraction recoveries,"The extraction recoveries of KET and NK were more than 81.23 ± 3.45% and 80.42 ± 4.57%, respectively.",Pharmacokinetic Effects of l-Tetrahydropalmatine on Ketamine in Rat Plasma by Ultraperformance Liquid Chromatography Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32724819/),%,81.23,242410,DB01114,Chlorphenamine
,32724819,extraction recoveries,"The extraction recoveries of KET and NK were more than 81.23 ± 3.45% and 80.42 ± 4.57%, respectively.",Pharmacokinetic Effects of l-Tetrahydropalmatine on Ketamine in Rat Plasma by Ultraperformance Liquid Chromatography Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32724819/),%,80.42,242411,DB01114,Chlorphenamine
,3685155,ED50,"The ED50 value for muricidal suppression at 1 hr was approximately 7.1 mg/kg (95% confidence limits, 5.4-9.3 mg/kg) after oral administration.",Muricidal suppression by chlorpheniramine and changes in brain levels following dietary-induced thiamine deficiency in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3685155/),[mg] / [kg],7.1,252198,DB01114,Chlorphenamine
,29169211,flow rate,The flow rate was set at 0.4 mL/min.,"Simultaneous determination of kaempferol, quercetin, mangiferin, gallic acid, p-hydroxybenzoic acid and chlorpheniramine maleate in rat plasma after oral administration of Mang-Guo-Zhi-Ke tablets by UHPLC-MS/MS and its application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29169211/),[ml] / [min],0.4,254892,DB01114,Chlorphenamine
,7341756,V1,"Harmonic mean of V1, Mss, Varea, CL, and terminal t 1/2 were 2.84, 10.8, and 15.5 liters/kg, and 4.14 liters/kg/hr and 2.57 hr, respectively.",Pharmacokinetics and tissue distribution of chlorpheniramine in rabbits after intravenous administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341756/),[l] / [kg],2.84,256578,DB01114,Chlorphenamine
,7341756,Mss,"Harmonic mean of V1, Mss, Varea, CL, and terminal t 1/2 were 2.84, 10.8, and 15.5 liters/kg, and 4.14 liters/kg/hr and 2.57 hr, respectively.",Pharmacokinetics and tissue distribution of chlorpheniramine in rabbits after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341756/),[l] / [h·kg],4.14,256579,DB01114,Chlorphenamine
,7341756,Varea,"Harmonic mean of V1, Mss, Varea, CL, and terminal t 1/2 were 2.84, 10.8, and 15.5 liters/kg, and 4.14 liters/kg/hr and 2.57 hr, respectively.",Pharmacokinetics and tissue distribution of chlorpheniramine in rabbits after intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341756/),[l] / [kg],10.8,256580,DB01114,Chlorphenamine
,7341756,Varea,"Harmonic mean of V1, Mss, Varea, CL, and terminal t 1/2 were 2.84, 10.8, and 15.5 liters/kg, and 4.14 liters/kg/hr and 2.57 hr, respectively.",Pharmacokinetics and tissue distribution of chlorpheniramine in rabbits after intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341756/),[l] / [h·kg],4.14,256581,DB01114,Chlorphenamine
,7341756,CL,"Harmonic mean of V1, Mss, Varea, CL, and terminal t 1/2 were 2.84, 10.8, and 15.5 liters/kg, and 4.14 liters/kg/hr and 2.57 hr, respectively.",Pharmacokinetics and tissue distribution of chlorpheniramine in rabbits after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341756/),[l] / [kg],10.8,256582,DB01114,Chlorphenamine
,7341756,CL,"Harmonic mean of V1, Mss, Varea, CL, and terminal t 1/2 were 2.84, 10.8, and 15.5 liters/kg, and 4.14 liters/kg/hr and 2.57 hr, respectively.",Pharmacokinetics and tissue distribution of chlorpheniramine in rabbits after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341756/),[l] / [h·kg],4.14,256583,DB01114,Chlorphenamine
,7341756,terminal t 1/2,"Harmonic mean of V1, Mss, Varea, CL, and terminal t 1/2 were 2.84, 10.8, and 15.5 liters/kg, and 4.14 liters/kg/hr and 2.57 hr, respectively.",Pharmacokinetics and tissue distribution of chlorpheniramine in rabbits after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341756/),[l] / [kg],15.5,256584,DB01114,Chlorphenamine
,7341756,terminal t 1/2,"Harmonic mean of V1, Mss, Varea, CL, and terminal t 1/2 were 2.84, 10.8, and 15.5 liters/kg, and 4.14 liters/kg/hr and 2.57 hr, respectively.",Pharmacokinetics and tissue distribution of chlorpheniramine in rabbits after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341756/),h,2.57,256585,DB01114,Chlorphenamine
,7341756,serum protein binding,The average serum protein binding was 44%.,Pharmacokinetics and tissue distribution of chlorpheniramine in rabbits after intravenous administration. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341756/),%,44,256586,DB01114,Chlorphenamine
,7341756,blood to plasma concentration ratio,The average blood to plasma concentration ratio was 1.85.,Pharmacokinetics and tissue distribution of chlorpheniramine in rabbits after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341756/),,1.85,256587,DB01114,Chlorphenamine
,7341756,hepatic blood extraction ratio,Estimated mean hepatic blood extraction ratio based on i.v. studies was 0.88.,Pharmacokinetics and tissue distribution of chlorpheniramine in rabbits after intravenous administration. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341756/),,0.88,256588,DB01114,Chlorphenamine
,19879084,run time,"After sample preparation by liquid-liquid extraction, the analytes and internal standard (diphenhydramine) were analyzed by reversed-phase HPLC on a Venusil Mp-C(18) column (50mmx4.6mm, 5microm) using formic acid:10mM ammonium acetate:methanol (1:40:60, v/v/v) as mobile phase in a run time of 2.6min.","Simultaneous quantitation of paracetamol, caffeine, pseudoephedrine, chlorpheniramine and cloperastine in human plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879084/),min,2.6,268828,DB01114,Chlorphenamine
